
Claims:

1. A compound of Formula I:



(I)

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer or isomer thereof,

wherein:

X^1 is independently CR^1R^2, NR^3, O, or C=O;

X^2 and X^4 are each independently CR^1R^2, C=O, S(O) or SO_2;

X^3 is $CR^{1'}R^{2'}$; wherein X^4, X^2, and X^1 are not all simultaneously CR^1R^2;

Y^1 and Y^4 are not bonded to –C(O)NHOH and are each independently N or CR^1;

Y^2 and Y^3 are each independently N or CR^1 when not bonded to –C(O)NHOH and Y^2 and Y^3, are C when bonded to –C(O)NHOH;

L is –C(O)–, $-C(O)(CR^1R^2)_m-$, or $-C(O)(CR^1R^2)_m-O-$, wherein L is bound to the ring nitrogen through the carbonyl group;

R is independently, and at each occurrence, H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_4-C_8 cycloalkenyl, C_2-C_6 alkynyl, C_3-C_8 cycloalkyl, C_5-C_{12} spirocycle, heterocyclyl, spiroheterocyclyl, aryl, or heteroaryl containing 1 to 5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, spirocycle, heterocyclyl, spiroheterocyclyl, aryl, or heteroaryl is optionally substituted with one or more OH, halogen, oxo, NO_2, CN, R^1, $-R^2$, OR^3, NHR^3, NR^3R^4,

~~$-S(O)_2NR^3R^4$, $-S(O)_2R^1$, $-C(O)R^1$, $-CO_2R^1$, $-NR^3S(O)_2R^1$, $-S(O)R^1$, $-S(O)NR^3R^4$, $-NR^3S(O)R^1$, heterocycle, aryl, or heteroaryl containing 1 to 5 heteroatoms selected from the group consisting of N, S, P, and O, with the proviso that R is not bound to L via a nitrogen atom;~~

~~each R^1 and R^2 are independently, at each occurrence, H, R^3, R^4, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_4-C_8 cycloalkenyl, C_2-C_6 alkynyl, C_3-C_8 cycloalkyl, heterocyclyl, aryl, heteroaryl containing 1 to 5 heteroatoms selected from the group consisting of N, S, P, and O, OH, halogen, NO_2, CN, NHC_1-C_6 alkyl, $N(C_1$-C_6 alkyl$)_2$, $S(O)_2N(C_1$-C_6 alkyl$)_2$, $N(C_1$-C_6 alkyl$)S(O)_2R^5$, $S(O)_2C_1$-C_6 alkyl, $(C_1$-C_6 alkyl$)S(O)_2R^5$, $C(O)C_1$-C_6 alkyl, CO_2C_1-C_6 alkyl, $N(C_1$-C_6 alkyl$)S(O)_2C_1$-C_6 alkyl, or $(CHR^5)_nNR^3R^4$, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from OH, halogen, NO_2, oxo, CN, R^5, OR^3, NHR^3, NR^3R^4, $S(O)_2N(R^3)_2$, $S(O)_2R^5$, $C(O)R^5$, CO_2R^5, $NR^3S(O)_2R^5$, $S(O)R^5$, $S(O)NR^3R^4$, $NR^3S(O)R^5$, heterocycle, aryl, and heteroaryl containing 1 to 5 heteroatoms selected from the group consisting of N, S, P, and O;~~

~~or R^1 and R^2 can combine with the atom to which they are both attached to form a spirocycle, spiroheterocycle, or a spirocycloalkenyl;~~

~~or R^1 and R^2, when on adjacent atoms, can combine to form a heterocycle, cycloalkyl, cycloalkenyl, aryl, or heteroaryl containing 1 to 5 heteroatoms selected from the group consisting of N, S, P, and O;~~

~~or R^1 and R^2, when on non-adjacent atoms, can combine to form a bridging cycloalkyl, cycloalkenyl, or heterocycloalkyl;~~

~~each $R^{1'}$ and $R^{2'}$ are each independently H, aryl, or heteroaryl containing 1 to 5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each aryl or heteroaryl is optionally substituted with one or more substituents selected from OH, halogen, NO_2, oxo, CN, R^3, R^5, OR^3, NHR^3, NR^3R^4, $S(O)_2N(R^3)_2$, $S(O)_2R^5$,~~

~~$-C(O)R^5$, $-CO_2R^5$, $-NR^3S(O)_2R^5$, $-S(O)R^5$, $-S(O)NR^3R^4$, $-NR^3S(O)R^5$, heterocycle, aryl, and heteroaryl containing 1 to 5 heteroatoms selected from the group consisting of N, S, P, and O, wherein at least one of $R^{1'}$ or $R^{2'}$ is not H;~~

~~R^3 and R^4 are independently, at each occurrence, H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_4-C_8 cycloalkenyl, C_2-C_6 alkynyl, C_3-C_8 cycloalkyl, heterocyclyl, aryl, heteroaryl containing 1 to 5 heteroatoms selected from the group consisting of N, S, P, and O, $-S(O)_2N(C_1$-C_6 alkyl$)_2$, $-S(O)_2C_1$-C_6 alkyl, $-(C_1$-C_6 alkyl$)S(O)_2R^5$, $-C(O)C_1$-C_6 alkyl, $-CO_2C_1$-C_6 alkyl, or $-(CHR^5)_nN(C_1$-C_6 alkyl$)_2$, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more substituents selected from OH, halogen, NO_2, oxo, CN, $-R^5$, $O(C_1$-$C_6)$ alkyl, $-NHC_1$-C_6 alkyl, $N(C_1$-C_6 alkyl$)_2$, $-S(O)_2N(C_1$-C_6 alkyl$)_2$, $-S(O)_2NH(C_1$-C_6 alkyl), $-C(O)C_1$-C_6 alkyl, $-CO_2C_1$-C_6 alkyl, $-N(C_1$-C_6 alkyl$)S(O)_2C_1$-C_6 alkyl, $-S(O)R^5$, $-S(O)N(C_1$-C_6 alkyl$)_2$, $-N(C_1$-C_6 alkyl$)S(O)R^5$, heterocycle, aryl, and heteroaryl containing 1 to 5 heteroatoms selected from the group consisting of N, S, P, and O;~~

~~R^5 is independently, at each occurrence, H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_4-C_8 cycloalkenyl, C_2-C_6 alkynyl, C_3-C_8 cycloalkyl, heterocyclyl, aryl, heteroaryl containing 1 to 5 heteroatoms selected from the group consisting of N, S, P, and O, OH, halogen, NO_2, CN, NHC_1-C_6 alkyl, $N(C_1$-C_6 alkyl$)_2$, $-S(O)_2NH(C_1$-C_6 alkyl), $-S(O)_2N(C_1$-C_6 alkyl$)_2$, $-S(O)_2C_1$-C_6 alkyl , $-C(O)C_1$-C_6 alkyl, $-CO_2C_1$-C_6 alkyl, $-N(C_1$-C_6 alkyl$)SO_2C_1$-C_6 alkyl, $-S(O)(C_1$-C_6 alkyl), $-S(O)N(C_1$-C_6 alkyl$)_2$, $-N(C_1$-C_6 alkyl$)S(O)(C_1$-C_6 alkyl) or $-(CH_2)_nN(C_1$-C_6 alkyl$)_2$; and~~


~~each n is independently and at each occurrence an integer from 0 to 6;~~

~~each m is independently and at each occurrence an integer from 1 to 6; and~~

~~provided that when X^2 and X^4 are both C=O, X^1 is not NR^3.~~

~~2. The compound of claim 1, wherein X^4 is CR^1R^2.~~

3. The compound of claim 1, wherein the compound is of the Formula IA:



(IA)

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer or stereoisomer thereof.


4. The compound of claim 3, wherein X^4 is CR^1R^2.

5. The compound of claim 3, wherein X^1 is NR^3, O, or C=O.

6. The compound of claim 3, wherein X^1 is O.


7. The compound of claim 3, wherein X^1 is O and X^4 is CR^1R^2.

8. The compound of claim 3, wherein the compound is of the Formula IA-1:




(IA-1).


~~9. The compound of claim 8, wherein the compound is of the Formula IA-1a, Formula IA-1b, or Formula IA-1c:~~



~~(IA-1a);~~




~~(IA-1b); or~~




~~(IA-1c).~~

~~10. The compound of claim 3, wherein the compound is of the Formula IA-2:~~




~~(IA-2).~~

~~11. The compound of claim 3, wherein the compound is of the Formula IA-3:~~




~~(IA-3).~~

~~12. The compound of claim 3, wherein the compound is of the Formula IA-4:~~




~~(IA-4).~~

~~13. The compound of claim 3, wherein the compound is of the Formula IA-5:~~




~~(IA-5).~~

~~14. The compound of claim 3, wherein the compound is of the Formula IA-6:~~




~~(IA-6).~~

~~15. The compound of claim 3, wherein the compound is of the Formula IA-7:~~




~~(IA-7).~~

~~16. The compound of claim 3, wherein the compound is of the Formula IA-8:~~




~~(IA-8).~~

~~17. The compound of claim 3, wherein the compound is of the Formula IA-9:~~




~~(IA-9).~~

~~18. The compound of claim 3, wherein the compound is of the Formula IA-10:~~




~~(IA-10).~~

~~19. The compound of claim 3, wherein the compound is of the Formula IA-11:~~



(IA-11).

20. The compound of claim 1, wherein the compound is of the Formula IB



(IB)

or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, enantiomer or stereoisomer thereof.

21. The compound of claim 20, wherein X^4 is CR^1R^2.


22. The compound of claim 20, wherein X^1 is NR^3, O, or C=O.

23. The compound of claim 20, wherein X^1 is O.

24. The compound of claim 20, wherein X^1 is O and X^4 is CR^1R^2.


25. The compound of claim 20, wherein X^1 is N, X^2 is C=O, and X^4 is CR^1R^2.

26. The compound of claim 20, wherein the compound is of the Formula IB-1:




~~(IB-1).~~

~~27. The compound of claim 20, wherein the compound is of the Formula IB-2:~~




~~(IB-2).~~

~~28. The compound of claim 20, wherein the compound is of the Formula (IB-3):~~




~~(IB-3).~~

~~29. The compound of claim 20, wherein the compound is of the Formula IB-4:~~



(IB-4).

30. The compound of claim 19, wherein the compound is of the Formula (IB-5):



(IB-5).

31. The compound of claim 1 selected from the group consisting of:

(S) N-hydroxy-3-phenyl-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;

(R) N-hydroxy-3-phenyl-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;

(S) N-hydroxy-4-(oxetane-3-carbonyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;

(3S)-4-(8-oxabicyclo[3.2.1]octane-3-carbonyl)-N-hydroxy-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;

(S)-4-(4-fluorotetrahydro-2H-pyran-4-carbonyl)-N-hydroxy-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;

~~(S)-4-(cyclohexanecarbonyl)-N-hydroxy-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-4-(cyclopentanecarbonyl)-N-hydroxy-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-4-(cyclobutanecarbonyl)-N-hydroxy-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-4-nicotinoyl-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-4-isonicotinoyl-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-4-(1-acetylpiperidine-4-carbonyl)-N-hydroxy-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-3-phenyl-4-((S)-tetrahydro-2H-pyran-3-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-3-phenyl-4-((R)-tetrahydro-2H-pyran-3-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-3-phenyl-4-((S)-tetrahydrofuran-3-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-3-phenyl-4-((R)-tetrahydrofuran-3-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-4-((1s,4R)-4-methoxycyclohexane-1-carbonyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-4-((1r,4S)-4-methoxycyclohexane-1-carbonyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-4-(1-methylpiperidine-4-carbonyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(1-methoxycyclopropane-1-carbonyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(2-methoxy-2-methylpropanoyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-3-phenyl-4-pivaloyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-3-phenyl-4-picolinoyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-isobutyryl-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(1-methoxycyclohexane-1-carbonyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-3-(4-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) 3-(3-fluorophenyl)-N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-3-(p-tolyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) 3-(4-chlorophenyl)-N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) 3-(3-chlorophenyl)-N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) 3-(4-fluorophenyl)-N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-3-(o-tolyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) N-hydroxy-3-(pyridin-3-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-3-(pyridin-3-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) 3-(2-fluorophenyl) N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) 3-(2-fluorophenyl) N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-3-(2-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-3-(2-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-3-(3-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-3-(3-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) 4-acetyl N-hydroxy-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) 4-(4-fluorobenzoyl) N-hydroxy-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(1-(methoxymethyl)cyclopropane-1-carbonyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide; and~~

~~(3S) N-hydroxy-3-phenyl-4-(tetrahydrofuran-2-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide.~~

~~32. The compound of claim 1 selected from the group consisting of~~

~~(S) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-3-(o-tolyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-3-(3-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-3-(3-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) 3-(3-fluorophenyl) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) 3-(3-fluorophenyl) N-hydroxy-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) 3-(3-fluorophenyl) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-3-(2-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-3-(2-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) 3-(2-fluorophenyl) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) 3-(2-fluorophenyl) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-3-(4-(trifluoromethyl)phenyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-3-(p-tolyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-3-(4-chlorophenyl)-N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-3-(3-chlorophenyl)-N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-3-(4-fluorophenyl)-N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-3-(quinoxalin-6-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-3-(quinolin-6-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-3-(quinolin-7-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-3-(naphthalen-2-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R)-N-hydroxy-3-(quinoxalin-6-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R)-N-hydroxy-3-(quinolin-6-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R)-N-hydroxy-3-(quinolin-7-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R)-N-hydroxy-3-(naphthalen-2-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-3-(quinoxalin-5-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-3-(quinolin-5-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-3-(quinolin-8-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S) N-hydroxy-3-(naphthalen-1-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) N-hydroxy-3-(quinoxalin-5-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R)-N-hydroxy-3-(quinolin-5-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R) N-hydroxy-3-(quinolin-8-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(R)-N-hydroxy-3-(naphthalen-1-yl)-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(3S) N-hydroxy-5-methyl-3-phenyl-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(3S)-N-hydroxy-5-methyl-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-6-fluoro-N-hydroxy-3-phenyl-4-(tetrahydro-2H-pyran-4-carbonyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-6-fluoro-N-hydroxy-4-(4-methyltetrahydro-2H-pyran-4-carbonyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-4-(3-methoxy-2,2-dimethylpropanoyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-4-(3-methoxy-3-methylbutanoyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

~~(S)-N-hydroxy-4-(3-hydroxy-3-methylbutanoyl)-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;~~

(S)-N-hydroxy-3-phenyl-4-(3-phenylpropanoyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;

(S)-N-hydroxy-3-phenyl-4-(4,4,4-trifluorobutanoyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;

(S)-N-hydroxy-3-phenyl-4-(3-(trifluoromethoxy)propanoyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;

(S)-N-hydroxy-3-phenyl-4-(3-(tetrahydro-2H-pyran-4-yl)propanoyl)-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide;

(S)-4-(3-(dimethylamino)propanoyl)-N-hydroxy-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide; and

(S)-4-(2,2-dimethyl-3-(tetrahydro-2H-pyran-4-yl)propanoyl)-N-hydroxy-3-phenyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepine-8-carboxamide.

33. A pharmaceutical composition comprising a compound of any one of claims 1 to 32 and a pharmaceutically acceptable carrier.

34. A method of treating a disease associated with HDAC6 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of claims 1 to 32.

35. The method of claim 34, wherein the disease is cancer, neurodegenerative disease, neurodevelopmental disorder, inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

~~36. The method of claim 35, wherein the cancer is cutaneous T-cell lymphoma, peripheral T-cell lymphoma, multiple myeloma, leukemia, lung, ovarian, breast, prostate, pancreatic, hepatocellular or renal cancer.~~

~~37. The method of claim 35, wherein the neurodegenerative disease is Alzheimer's, Huntington's, Parkinson's, Amyotrophic Lateral Sclerosis, or spinal muscular atrophy.~~

~~38. The method of claim 35, wherein the neurodevelopmental disorder is Rett syndrome.~~

~~39. The method of claim 35, wherein the inflammatory or autoimmune disease is rheumatoid arthritis, spondylitis arthritis, psoriatic arthritis, psoriasis, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel diseases, graft versus host disease, transplant rejection or fibrotic disease.~~

~~40. The method of claim 34, wherein the compound inhibits a histone deacetylase.~~


~~41. The method of claim 34, wherein the compound inhibits a zinc-dependent histone deacetylase.~~

~~42. The method of claim 34, wherein the compound inhibits the HDAC6 isozyme zinc-dependent histone deacetylase.~~

~~43. A compound of any one of claims 1 to 32 for use in treating or preventing a disease associated with HDAC6 modulation.~~

~~44. Use of a compound of any one of claims 1 to 32 in the manufacture of a medicament for treating or preventing a disease associated with HDAC6 modulation.~~

1. A compound:



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.